Orion Corporation: Disclosure Under Chapter 9 Section 10 of the Securities Market Act (BlackRock, Inc.)
ORION CORPORATION STOCK EXCHANGE RELEASE / MAJOR SHAREHOLDER ANNOUNCEMENTS27 MAY 2021 at 18.50 EEST
OSE Immunotherapeutics and the FoRT Foundation Announce Initiation of a Phase 2 Clinical Trial Evaluating Tedopi® in Combination with Opdivo®…
NANTES, France and ROME, May 27, 2021 (GLOBE NEWSWIRE) -- OSE Immunotherapeutics (ISIN: FR0012127173; Mnemo: OSE) and the FoRT Foundation (Fondazione Ricerca Traslazionale) today announced that the Italian Medicines Agency (AIFA) and the Italian Ethics Committee approved the initiation of a new Phase 2 clinical trial evaluating Tedopi® in combination with Opdivo® or chemotherapy as second-line treatment in patients with metastatic non-small cell lung cancer (NSCLC).
The rest is here:
OSE Immunotherapeutics and the FoRT Foundation Announce Initiation of a Phase 2 Clinical Trial Evaluating Tedopi® in Combination with Opdivo®...
Kane Biotech Announces First Quarter 2021 Financial Results
WINNIPEG, Manitoba, May 27, 2021 (GLOBE NEWSWIRE) -- Kane Biotech Inc. (TSX- V:KNE; OTCQB:KNBIF) (the “Company” or “Kane Biotech”), today announced first quarter 2021 financial results.
Read this article:
Kane Biotech Announces First Quarter 2021 Financial Results
Galapagos to present data on rheumatoid arthritis at the upcoming European League Against Rheumatism (EULAR) congress
Mechelen, Belgium, 27 May 2021, 22:01 CET, – Galapagos NV (Euronext & Nasdaq: GLPG) today announced that 15 abstracts, including scientific updates, and data providing further understanding on the profile of filgotinib as a treatment for people with Rheumatoid Arthritis (RA), will be presented at the European League Against Rheumatism (EULAR) virtual congress 2021, 2-5 June.
Ascendis Pharma A/S Reports First Quarter 2021 Financial Results
– Pre-launch activities continue in preparation for a potential FDA approval of TransCon™ hGH (lonapegsomatropin) for pediatric growth hormone deficiency; PDUFA date of June 25, 2021 –
Read more here:
Ascendis Pharma A/S Reports First Quarter 2021 Financial Results
Biomea Fusion Reports First Quarter 2021 Financial Results and Business Highlights
-- Received $167 million in aggregate gross proceeds in April from initial public offering --– Advancing lead oncology program BMF-219, a small molecule irreversible menin inhibitor, toward IND filing in second half of 2021 --
Go here to see the original:
Biomea Fusion Reports First Quarter 2021 Financial Results and Business Highlights
Vaxcyte to Present at the Jefferies Virtual Healthcare Conference
FOSTER CITY, Calif., May 27, 2021 (GLOBE NEWSWIRE) -- Vaxcyte, Inc. (Nasdaq: PCVX), a next-generation vaccine company seeking to improve global health by developing superior and novel vaccines designed to prevent or treat some of the most common and deadly infectious diseases worldwide, today announced that Company management will present at the Jefferies Virtual Healthcare Conference on Thursday, June 3, 2021 at 4:00pm ET.
See the original post:
Vaxcyte to Present at the Jefferies Virtual Healthcare Conference
Chiasma Presents Positive Patient-Reported Outcomes Data from its MPOWERED™ Phase 3 Trial Comparing MYCAPSSA® to Long-Acting Injectables for the…
--Data presented at AACE 2021 demonstrate patient quality of life and work productivity significantly improved in patients transitioning from injectable SSAs to MYCAPSSA®-- --Data presented at AACE 2021 demonstrate patient quality of life and work productivity significantly improved in patients transitioning from injectable SSAs to MYCAPSSA®--
GENFIT Informs its Shareholders of Certain Procedures for the Combined General Meeting of June 15, 2021
Lille, France; Cambridge, MA; May 27, 2021 - GENFIT (Nasdaq and Euronext: GNFT), a late-stage biopharmaceutical company dedicated to improving the lives of patients with metabolic and liver diseases (the “Company”), today informs its shareholders of certain participation and organization procedures for the ordinary and extraordinary general meeting of June 15, 2021 (the “Combined General Meeting”) in accordance with decree n°2021-255 of March 9, 2021, extending the application of measures of ordinance n°2020-321 of March 25, 2020 and its application decree n°2020-418 of April 10, 2020 which was extended until July 31, 2021 by the decree n°2021-255 of March 9, 2021 (the “Decree”).
Read more here:
GENFIT Informs its Shareholders of Certain Procedures for the Combined General Meeting of June 15, 2021
AnaptysBio to Present at the 2021 Jefferies Virtual Healthcare Conference
SAN DIEGO, May 27, 2021 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company developing first-in-class antibody product candidates focused on emerging immune control mechanisms applicable to inflammation and immuno-oncology indications, today announced that Hamza Suria, chief executive officer of AnaptysBio, will present at the Jefferies Virtual Healthcare Conference on Thursday, June 3, 2021 at 1:30 p.m. ET. The conference will be conducted virtually, and the audio presentation will be available via: https://wsw.com/webcast/jeff174/anab/1811646.
Follow this link:
AnaptysBio to Present at the 2021 Jefferies Virtual Healthcare Conference